Trending

BMS

BMS gets new OK for Opdivo/Yervoy in kidney cancer

BMS gets new OK for Opdivo/Yervoy in kidney cancer

Bristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green

X

BMS gets new OK for Opdivo/Yervoy in kidney cancer

https://pharmaphorum.com/news/bms-gets-new-ok-for-opdivo-yervoy-in-kidney-cancer/

2019 M&A starts with a bang as BMS and Celgene agree $74bn merger

2019 M&A starts with a bang as BMS and Celgene agree $74bn merger

Bristol-Myers Squibb has agreed a $74 billion deal to merge with Celgene in a deal that will boost

X

2019 M&A starts with a bang as BMS and Celgene agree $74bn merger

https://pharmaphorum.com/news/2019-ma-starts-with-a-bang-as-bms-agrees-74bn-merger-with-celgene/

BMS confirms Taisho’s $1.6bn offer for UPSA

BMS confirms Taisho’s $1.6bn offer for UPSA

After protracted speculation, Bristol-Myers Squibb has confirmed it plans to divest its French over-the-counter (OTC) medicines business UPSA

X

BMS confirms Taisho’s $1.6bn offer for UPSA

https://pharmaphorum.com/news/bms-confirms-taishos-1-6bn-offer-for-upsa/

BMS looks to RNA splicing to boost immunotherapies

BMS looks to RNA splicing to boost immunotherapies

Bristol-Myers Squibb’s quest to claim dominance in the immunotherapy space continues through a new collaboration with Eisai and

X

BMS looks to RNA splicing to boost immunotherapies

https://pharmaphorum.com/news/bms-looks-to-rna-splicing-to-boost-immunotherapies/

Pfizer might buy BMS for $130bn – but should it?

Pfizer might buy BMS for $130bn – but should it?

Pfizer could soon launch a multi-billion dollar bid for immunotherapy rivals Bristol-Myers Squibb. But moves into new fields

X

Pfizer might buy BMS for $130bn – but should it?

https://pharmaphorum.com/news/pfizer-might-buy-bms-for-130bn-but-should-it/

BMS strikes back with lung cancer combo success

BMS strikes back with lung cancer combo success

Just as it looked like Bristol Myers Squibb might never catch up with its rivals in frontline lung cancer treatment, the company has achieved success in a new combination.

X

BMS strikes back with lung cancer combo success

https://pharmaphorum.com/news/bms-strikes-back-lung-cancer-combo-success/

BMS and Infinity aim to overcome triple negative breast cancer resistance to IO

BMS and Infinity aim to overcome triple negative breast cancer resistance to IO

BMS is looking to get ahead of its rival Merck & Co. by overcoming resistance to PD-1 immunotherapy

X

BMS and Infinity aim to overcome triple negative breast cancer resistance to IO

https://pharmaphorum.com/news/bms-infinity-aim-overcome-triple-negative-breast-cancer-resistance-io/

BMS and Roche look to Halozyme drug delivery for IO advantage

BMS and Roche look to Halozyme drug delivery for IO advantage

Bristol-Myers Squibb is to work with drug delivery specialist Halozyme to create an injectable form of its blockbuster

X

BMS and Roche look to Halozyme drug delivery for IO advantage

https://pharmaphorum.com/news/bms-roche-look-halozyme-drug-delivery-io-advantage/

Clovis and BMS combine cancer drugs in late-stage trials

Clovis and BMS combine cancer drugs in late-stage trials

Clovis and BMS research small molecule and antibody combination.

X

Clovis and BMS combine cancer drugs in late-stage trials

https://pharmaphorum.com/news/clovis-bms-cancer/

1 2 3

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com